Kling Bio has announced a new collaboration and licence option agreement with Sanofi to accelerate the discovery of neutralising antibodies using its proprietary B cell platform, Kling-Select.

Kling Bio has entered a partnership and licence option agreement with Sanofi to discover neutralising antibodies and epitopes.

Dutch privately-held biotech Kling Bio today announced it has entered into a collaboration and license option agreement with French pharma major Sanofi for the discovery of antibodies and epitopes ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma  Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

Sanofi’s Sarclisa receives European approval to treat transplant-eligible newly diagnosed multiple myeloma: Paris Saturday, July 26, 2025, 09:00 Hrs [IST] Following the positive ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Sanofi's $1.6B acquisition ...

A major scientific breakthrough has identified the Epstein-Barr virus (EBV) as the leading cause of multiple sclerosis (MS), a chronic inflammatory disease that affects nearly 3 million people ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...